STAT+: Why Novartis is changing the name of its research labs
Swiss drugmaker Novartis’ research and development hub has a new name — and a new…
Category: STAT+
Opinion: STAT+: Sanofi CEO Paul Hudson: The right way to bring AI into pharma
While it’s widely accepted that the pharma industry is innovative in R&D, it is also…
STAT+: Amazon’s chief medical officers on where the company’s health care bets are headed next
The graveyard is littered with Amazon’s bets in health care: wearables, Care, the ill-fated Haven….
STAT+: Pharmalittle: South Africa ‘bullied’ into one-sided Covid vaccine deals; Astellas drops Medicare price-negotiation suit
Good morning, everyone. Jason Mast here filling in for Ed. I learned today from TikTok…
STAT+: In boon for scientists, U.K. strikes deal to join E.U. Horizon research program
The U.K. has reached a deal to join the E.U.’s landmark Horizon research initiative, a…
STAT+: Why the drug industry’s opaque warnings on price negotiations fall short
Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry…
STAT+: AstraZeneca CEO Pascal Soriot proposes a novel fix to the drug pricing bill’s alleged cancer problem
Among the pharmaceutical companies’ many objections to the Biden administration’s drug pricing program is a…
STAT+: Cancer care appears brighter as off-the-shelf CAR-T advances
If you ask biopharma leaders what’s ahead for CAR-T cancer therapy, they say the future…
STAT+: South Africa was forced into ‘one-sided’ deals with Covid-19 vaccine suppliers, contracts reveal
South Africa was “bullied” into signing one-sided contracts with Covid-19 vaccine suppliers that forced the…
.jpg)
STAT+: House committees strike deal on health transparency, PBM reform package
WASHINGTON — Republicans on three key House committees have reconciled their differing legislative packages to…
STAT+: Covid hospitalizations on the rise, Humana says
More older adults have been hospitalized for Covid-19 over the past several weeks, according to…
STAT+: Astellas withdraws lawsuit after evading Medicare drug price negotiations
WASHINGTON — Astellas was so sure that one of its drugs was going to be…
STAT+: Nimbus Therapeutics raises $210 million in one of the larger fundraising rounds this year
Seven months after Nimbus Therapeutics sold an experimental autoimmune disease medicine to Takeda Pharmaceuticals for up to…
STAT+: Pharmalittle: Novartis is losing its chief commercial officer; vaccine experts urge more inclusivity in clinical trials
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: Pharmalittle: Novartis is latest drugmaker to sue over Medicare negotiations; Illumina names a new CEO
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT+: Illumina names Agilent executive as new CEO
Illumina, the largest maker of DNA-sequencing technology and a storied name in the biotechnology industry,…
STAT+: Graduate students accuse University of California of wage theft, just months after strike was settled
University of California graduate students were thrilled last December when they won what they thought…
STAT+: Generative AI Tracker: A guide to the health systems and companies driving adoption
Health care leaders and technology companies are investing heavily in large language models, a powerful…
STAT+: Moving beyond ChatGPT: How generative AI is inspiring dreams of a health data revolution
The world’s largest technology companies are racing to build generative AI into every corner of…
STAT+: Humana sues Biden administration over Medicare Advantage audit rule
Humana sued the federal government Friday, arguing that this year’s new rule to claw back…
STAT+: FTC settles with Amgen over $28 billion deal for Horizon
After months of legal sparring, Amgen and Horizon Therapeutics settled a lawsuit with the U.S….
STAT+: Pharmalittle: How 98 days may cost J&J big bucks; Walgreens CEO departs
And so, another working week will soon draw to a close. Not a moment too…
STAT+: AstraZeneca bets that gene therapy’s workhorse will still deliver the goods
Seng Cheng has been working in gene therapy for nearly as long as gene therapy…
STAT+: The curious case of J&J’s Stelara, the unluckiest drug on Medicare’s list
WASHINGTON — Ninety-eight days may end up costing Johnson & Johnson. When Medicare this week…
STAT+: A new paper suggests a simple fix to the primary care physician shortage
The U.S. is running low on primary care physicians, with an estimated shortage of between…
STAT+: Sly CAR-T strategy evades ‘fratricide’ problem to aim at all blood cancers
The problem with the plan was fratricide, among other wanton cellular murders. Saar Gill and…
STAT+: Departing Stanford president retracts two widely cited papers, against lead author’s wishes
After an expansive investigation found manipulated data and other issues with papers co-authored by Stanford’s…
.jpg)
STAT+: Drug firms test medicines to halt Alzheimer’s before symptoms appear
Alzheimer’s disease has killed at least three women in Astrida Schaeffer’s family over two generations,…
STAT+: Pharmalittle: U.S. pharma layoffs continue to climb; senators push insulin makers for details of low-cost programs
Top of the morning to you, and a fine one it is. Blue skies and…
STAT+: As pharmaceutical companies bemoan Medicare’s drug negotiations, hospitals and doctors stay mum
The pharmaceutical industry has been up in arms over Medicare’s first list of 10 prescription…
STAT+: Unicorn down: Following layoffs, Biofourmis CEO quietly departs
A month after conducting significant layoffs, Biofourmis is out a CEO: Kuldeep Singh Rajput, one…
STAT+: J&J cuts the price of its life-saving TB pill by more than half for many low and middle-income countries
Amid controversy over access to a life-saving tuberculosis pill, a new contracting effort is expected…
STAT+: Pharmalittle: Winners and losers from Medicare drug-negotiation list; Novo strikes deal to keep lead in weight-loss drugs
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Workforce, capacity constraints slow ramp-up of new Alzheimer’s drug Leqembi
The first Alzheimer’s therapy to clearly slow cognitive decline, approved in the United States last…
STAT+: KRAS, the ideal cancer drug target that became ‘undruggable,’ takes on a new glow
On Target is a recurring feature from STAT that dives deep into the most promising…
STAT+: Winners and losers from Medicare’s list of drugs subject to price negotiation
On Tuesday morning, the U.S. Department of Health and Human Services unveiled its long-awaited list…
STAT+: Pharmalittle: U.S. selects first 10 drugs for Medicare price negotiations; Pfizer may soon restart tornado-hit plant
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: As competition looms, Insulet sues a rival for allegedly stealing trade secrets on diabetes tech
Insulet filed a lawsuit this month against its rival EOFlow, accusing it of stealing trade…
STAT+: FDA delays enforcement of a pharmaceutical supply chain law to stop counterfeit drugs
In response to growing complaints, the U.S. Food and Drug Administration has postponed its plans…
STAT+: Pharmalittle: FTC suspends challenge to Amgen deal for Horizon; AstraZeneca is latest to challenge Medicare drug negotiations
Good morning, everyone, and nice to see you again after a week-long respite, during which…
STAT+: Feds fine Medicare Advantage plans for overcharging their members
The federal government has started penalizing Medicare Advantage insurers that have one common, glaring problem:…
STAT+: Neuroscience startup Neumora files for IPO
Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of…
STAT+: AstraZeneca sues to immediately stop Medicare drug price negotiation program
WASHINGTON — AstraZeneca is the sixth drug maker to pile on a legal challenge to…
STAT+: Weight loss drug Wegovy improves function in people with common type of heart failure
Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of…
STAT+: NYU launched private ChatGPT for its health data, and set its staff loose to experiment
NEW YORK — A fourth-year medical student, a music therapist, a child psychiatrist, and a…
STAT+: Drug makers already bet big on mRNA for cancer. Why is Biden going in, too?
WASHINGTON — President Biden’s fledgling health agency, designed to accelerate under-funded research, just set its…
STAT+: What past blockbusters can tell us about future of Wegovy and other weight loss medicines
The news that the weight loss drug Wegovy reduced the risk of heart attacks and…
STAT+: FDA panel votes against high blood pressure device from Medtronic, but lends support to ReCor Medical’s
An advisory panel to the Food and Drug Administration delivered a split decision on a…
STAT+: Ron DeSantis wants to import drugs from Canada. Biden’s FDA just blasted his plan
WASHINGTON — Florida governor and presidential hopeful Ron DeSantis has ballyhooed a high-profile plan to…
STAT+: Pharmalittle: Roche data on immunotherapy accidentally released; Novo Nordisk hires Thermo Fisher to manufacture Wegovy
Hello and happy Wednesday from STAT’s London outpost, with Andrew Joseph here filling in for…